No Data
The intrinsic growth gene of Deqi Pharmaceuticals-B (6996.HK) is hidden in the differentiated global equity innovation pipeline.
As an investor who has been tracking the Hong Kong stock market's innovative drugs sector for a long time, the performance of the innovative drugs sector in recent years has not been outstanding. The secondary market has shifted from eliminating valuation bubbles to irrationally suppressing valuations.
Express News | Antengene Corporation H1 Net Income RMB -167 Million
Express News | Antengene Corporation H1 Revenue RMB 60.8 Million
ANTENGENE-B: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED JUNE 30, 2024
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
No Data
